• January 06, 2021

  Kowa Company, Ltd. has renewed its corporate website.

• August 26, 2020

  K-115 (Ripasudil Hydrochloride Hydrate), a Rho Kinase Inhibitor, has been approved in Thailand

• July 13, 2020

  K-115 (Ripasudil Hydrochloride Hydrate), a Rho Kinase Inhibitor, has been approved in Malaysia

• March 11, 2020

  K-115 (Ripasudil Hydrochloride Hydrate), a Rho Kinase Inhibitor, has been approved in Singapore

• February 19, 2020

  Fixed Combination Eye Drop of Ripasudil Hydrochloride Hydrate, a Rho Kinase Inhibitor, and Brimonidine Tartrate Started Phase 3 Clinical Studies in Japan
  [Developmental code: K-232]

• August 07, 2014

  University of Tokyo's RCAST, Fujitsu, and Kowa
  Successfully Generate a Novel Active Compound Targeting Cancer Using IT-based Drug Discovery Technology

• December 24, 2013

  December 11, 2013 - Yoshihiro Miwa, President & C.E.O. of KOWA, was honored the chair engraved with the Brigham and Women’s Hospital (BWH) logo. This chair indicates the contribution toward the medical development from BWH that operates joint research facility with KOWA.

• October 26, 2012

  License Agreement of SGLT2 Inhibitor "CSG452" in Japan

• June 06, 2012

  A consolidated subsidiary of Mitsubishi Tanabe Pharma, Tai Tien Pharmaceuticals Co., Ltd., started marketing Livalo (pitavastatin), a hypercholesterolemia treatment agent (an HMG-CoA reductase inhibitor), in Taiwan on June 1, 2012.
  A regulatory approval was obtained in January 2011.

• May 09, 2012

  A consolidated subsidiary of Mitsubishi Tanabe Pharma，P.T. Tanabe Indonesia，started marketing Livalo (pitavastatin)，a hypercholesterolemia treatment agent (an HMG-CoA reductase inhibitor)，in Indonesia on May 1，2012.
  The launch comes after P.T. Tanabe Indonesia received regulatory approval in November 2011.

• February 20, 2012

  Eli Lilly has introduced Redevant (pitavastatin), an HMG-CoA reductase inhibitor for lowering cholesterol, in Mexico this month.
  The launch comes after the product received approval in July 2011 from the country's Ministry of Health.

• November 10, 2011

  Kowa Announces the Efficacy and Safety of a Novel Phosphodiesterase 3 Inhibitor K-134 for the Treatment of Intermittent Claudication in AHA 2011

• August 04, 2011

  Mexican health authority has granted marketing authorization for pitavastatin，an HMG-CoA reductase inhibitor or statin，for treatment of hyperlipidemia.
  Kowa’s partner，Eli Lilly will market the product as Redevant® from early 2012.

• May 11, 2011

  The HMG-CoA reductase inhibitor pitavastatin calcium (Livazo 1mg, 2mg & 4mg) has been launched in Spain on May 2, 2011 as the first European market.
  Spain is co-marketed by Recordati S.p.A and ESTEVE

• May 09, 2011

  Kowa Announces the Efficacy and Safety of a Novel Rho Kinase Inhibitor (K-115) in the Treatment of Glaucoma－The Association for Research in Vision and Ophthalmology (ARVO) 2011－

• April 28, 2011

  Contracts of BBHP (Bare Boat Hire & Purchase) have been entered into successfully with Adani Group for 2 bulk carrier vessels of Cape-size.
  The BBHP being effective for 10 years period to the 2 vessels, each with 180,000 DWT type bulk carrier respectively and will be completed its construction in the year of 2012, which we have worked it for these months with Adani Group, now has been mutually agreed in final and signed on April 28, 2011.
  We shall proceed and develop our business more and more at the various sites of business with Adani Group.

• January 28, 2011

  We have made and entered into a Contract of "Business Alliance" on Jan.28, 2011, with Adani Group who is one of India's fastest-growing business houses.
  By the contract we will act as the navigator for any of Japanese companies and manufacturers who intend to advance to the Economic Free Zone that is developed and managed by Adani Group in India.
  And furthermore we will act as the coordinator for any of Japanese companies who desire to sell or buy any products procured by Adani Group.
  We will contribute, so as above, in aggressive attitude, to any of penetration, investment, and/or products-export/import, to/from India for the benefit of Japanese enterprises.

• January 24, 2011

  Subgroup Analyses of Peretinoin (NIK-333) Phase II/III Trial in Patients Following Curative Therapy for Hepatocellular Carcinoma (HCC) Indicate Populations Who May Gain Most Benefit from Peretinoin Therapy.
  Peretinoin may reduce de novo carcinogenesis.
  Presented at American Society of Clinical Oncology Gastrointestinal Cancers Symposium 2011

• January 19, 2011

  Peretinoin (NIK-333) Study Subanalysis Gives Clue To Mechanism of Reduced Recurrence of Hepatocellular Carcinoma (HCC), To Be Presented at American Society of Clinical Oncology Gastrointestinal Cancers Symposium 2011

• October 20, 2010

  Peretinoin（NIK-333）Data, the Results of the Clinical Pharmacology Study for Liver Gene Expression Profiles in Patients after Curative Therapy of Hepatocellular Carcinoma (HCC), To Be Presented at The 61st Annual Meeting of the American Association for the Study of Liver Diseases

• September 13, 2010

  Peretinoin reduces recurrence risk of hepatocellular carcinoma after curative therapy
  The results of a Phase II/III trial presented at the International Liver Cancer Association Fourth Annual Conference

• August 30, 2010

  Peretinoin（NIK-333）Data, the Results of the Phase II/III Trial for the Suppression of Recurrence of Hepatocellular Carcinoma (HCC), To Be Presented at the International Liver Cancer Association Annual Conference

• July 29, 2010

  New English Website Launch!

• July 29, 2010

  New Telephoto Scope will be exhibited !!·British Birdwatching Fair 2010 (BBWF)
  ·August 20-22, 2010
  ·Rutland Water (U.K.)

• July 29, 2010

  New 2D/3D Non-mydriatic retinal camera "nonmydWX" will be exhibited!·European Society of Cataract & Refractive Surgerons(ESCRS 2010)
  ·September 4-8, 2010
  ·Paris(France)

• July 29, 2010

  New 2D/3D Non-mydriatic retinal camera "nonmydWX" will be exhibited!·Asia Pacific Academy of Ophthalmology(APAO 2010)
  ·September 16-20, 2010
  ·Beijing(China)

• July 29, 2010

  New Telephoto Scope will be exhibited !!·Photokina 2010
  ·September 21-26, 2010
  ·Cologne (Germany)

• July 29, 2010

  Several New Products will be exhibited !!·Security Essen 2010
  ·October 5-8, 2010
  ·Essen(Germany)

• July 29, 2010

  Several New Products will be exhibited !!·ASIS 2010
  ·October 12-14, 2010
  ·Dallas(U.S.A.)

• July 29, 2010

  New 2D/3D Non-mydriatic retinal camera "nonmydWX" will be exhibited!·American Academy of Ophthalmology(AAO 2010)
  ·October 16-19, 2010
  ·Chicago(U.S.A.)

• December 24, 2009

  Kowa Company, Ltd. Opens Collaborative Cardiovascular Research Center with Brigham and Women's HospitalKowa Company, Ltd. headquartered in Nagoya, Japan (Kowa) and Brigham and Women's Hospital (BWH), December 23, 2009, open The Center for Interdisciplinary Cardiovascular Sciences (CICS) in the Center for Life Science, 3 Blackfan Street in the Longwood Medical Area of Boston.
  CICS is collaborative research center where scientists from Kowa and BWH as a Harvard-affiliated hospital will work collaboratively for discovery and advancement in cardiovascular research.

• August 3, 2009

  FDA Approves LIVALO® for Primary Hypercholesterolemia and Combined DyslipidemiaFDA Approves LIVALO® for Primary Hypercholesterolemia and Combined Dyslipidemia.
  Montgomery, AL and Morrisville, NC August 03, 2009 - Kowa Research Institute (KRI)based in Morrisville, NC and Kowa Pharmaceuticals America, Inc. (KPA), a privately-held specialty pharmaceutical company headquartered in Montgomery, AL, announced today that the U.S. Food and Drug Administration (FDA) has approved LIVALO® (pitavastatin), a potent HMG-CoA reductase inhibitor (statin), for the primary treatment of hypercholesterolemia and combined dyslipidemia.